Clinical Study
Efzofitimod: A Study Drug for People with Pulmonary Sarcoidosis
Pulmonary Sarcoidosis is a disease that most commonly affects the lungs and causes other health conditions that impact a persons quality of life. Efzofitimod is a study drug to help people with this disease. Research is needed to learn the safety and effectiveness of the drug. The information we gain may aid future patients.
For more information contact:
Chloe Kirkpatrick
chloe.kirkpatrick@hsc.utah.edu
801-581-5811
IRB#: IRB_00156634
| PI: BRITTANY SCARPATO
| Department: PULMONARY
| Approval Date: 2023-01-11 07:00:00
Specialties: Pulmonary
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Ages 18 years and older
- History of Pulmonary Sarcoidosis
- Receiving treatment with oral corticosteroids for 3 months or longer prior to when you start the study and receiving the same dose for 4 weeks or longer prior to starting the study
- Willing to lessen and then stop the dose of oral corticosteroid
- Willing to use birth control during the study
Exclusion Criteria:
- Treatment with more than 1 immunosuppressant therapy
- Major surgery or hospitalization in the past 3 months prior to starting participation in the study or scheduled surgery during the study
- Active, heavy smoker of tobacco/nicotine-containing products (defined as greater than 20 cigarettes/day or e-cigarette equivalent)
- Active substance abuse or history of substance abuse
- Pregnant
Will I be paid for my time?
Yes